This Article Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Request Permissions Citing Articles Citing Articles via Google Scholar Google Scholar Articles by JUDSON, W. E. Articles by WILKINS, R. W. Search for Related Content PubMed PubMed Citation Articles by JUDSON, W. E. Articles by WILKINS, R. W.

(Circulation. 1956;13:553.)
© 1956 American Heart Association, Inc.

---

Observations on Angina Pectoris during Drug Treatment of Hypertension

WALTER E. JUDSON M.D.¹; WILLIAM HOLLANDER M.D.¹; ROBERT W. WILKINS M.D.¹

¹ From the Robert Dawson Evans Memorial Department of Clinical Research and Preventive Medicine, Massachusetts Memorial Hospitals, and the Department of Medicine, Boston University School of Medicine, Boston, Massachusetts.

Antihypertensive drug treatment is capable of aggravating angina pectoris in hypertensive patients with coronary artery disease. The complication appears to be due to different hemodynamic mechanisms. Angina pectoris caused by hydralazine may result not only from a reduction in aortic perfusion pressure but also from increases in cardiac output and pulse rate which the drug produces. Coronary insufficiency, after the administration of hexamethonium, is usually associated with severe hypotension and results primarily from a reduction in aortic perfusion pressure. Hexamethonium was not found to prevent the anginal effects of hydralazine. Intravenous hydralazine is a sensitive test for coronary insufficiency but is not without untoward reactions.